RB1 and breast carcinoma: Additionally, recent research found that the presence of tumor DNA alterations in FANCC (a member of the FA pathway), ATM, and RB1 predicted beneficial response to cisplatin neoadjuvant chemotherapy.52 Future research could determine whether FA nonsense mutations also predict beneficial response to Cisplatin, particularly given the beneficial response to cisplatin in patients with BRCA1 mutant breast cancers.53